Eye Floaters News and Research

RSS

Eye floaters (myodesopsias) emerge as a consequence of opacities developed in the vitreous fluid of the eye.

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

ThromboGenics receives FDA approval for Jetrea to treat symptomatic vitreomacular adhesion

On Oct. 17, the U.S. Food and Drug Administration approved Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

19 Oct 2012

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Eye Floaters News and Research

Further Reading

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

ThromboGenics receives FDA approval for Jetrea to treat symptomatic vitreomacular adhesion

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News